8-K: Elicio Therapeutics Completes Enrollment in Phase 2 Trial for Pancreatic Cancer Vaccine

Elicio Therapeutics has completed enrollment of 135 patients in its Phase 2 AMPLIFY-7P study evaluating ELI-002 for pancreatic cancer, with interim results expected in the first half of 2025.

Summary

• Elicio Therapeutics has finished enrolling patients in its Phase 2 AMPLIFY-7P study for ELI-002, a cancer vaccine targeting mutant KRAS-driven pancreatic cancer.
• The study enrolled 135 patients with pancreatic ductal adenocarcinoma (PDAC) who are at high risk of relapse after surgery.
• Patients were randomized 2:1 to receive ELI-002 7P or standard of care observation, with the option for observation patients to cross over to the treatment arm upon disease progression.
• The primary endpoint of the study is disease-free survival (DFS), with secondary endpoints including tumor biomarker responses, overall survival, and vaccine immunogenicity.
• An interim analysis of the data, including DFS, is expected in the first half of 2025, with potential outcomes including reporting primary endpoint analysis, continuing to final DFS analysis, or meeting futility criteria.
• The first patient was dosed in January 2024.

Sentiment

Score: 7

Explanation: The document is positive due to the completion of enrollment ahead of schedule and the potential of the ELI-002 vaccine, but there are risks associated with clinical trials and the company's financial condition.

Positives

• The speed of study enrollment exceeded expectations, indicating strong interest from investigators and patients.
• The study is evaluating an off-the-shelf monotherapy treatment option for patients who have completed standard chemotherapy.
• The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations.
• The company's AMP technology aims to enhance the immune response compared to conventional vaccination strategies.

Risks

• The study results are not yet available, and the interim analysis in the first half of 2025 could result in the study being stopped if futility criteria are met.
• The company's financial condition and ability to obtain funding are risks to the development of ELI-002 and other product candidates.
• There is a risk that actual results may differ materially from forward-looking statements due to various factors.

Future Outlook

Elicio is focused on the interim data analysis in the first half of 2025 and is working to bring the ELI-002 vaccine to cancer patients. The company also intends to develop additional off-the-shelf therapeutic cancer vaccines.

Management Comments

• Christopher Haqq, M.D., Ph.D., stated that the speed of study enrollment exceeded expectations, reflecting high levels of investigator and patient interest.
• Management is eagerly looking forward to the pre-planned interim data analysis.

Industry Context

The announcement is relevant to the broader trend of developing novel immunotherapies for cancer treatment, particularly in the area of personalized cancer vaccines and off-the-shelf solutions. The focus on KRAS mutations is significant as they are a common driver of many solid tumors.

Comparison to Industry Standards

• Elicio's approach of using an off-the-shelf vaccine targeting common KRAS mutations is similar to other companies developing personalized cancer vaccines, but Elicio's AMP technology aims to enhance the immune response.
• The study design, with a randomized control arm and a crossover option, is consistent with industry standards for Phase 2 clinical trials.
• The focus on disease-free survival as a primary endpoint is common in cancer vaccine trials.
• Companies like BioNTech and Moderna are also developing mRNA-based cancer vaccines, but Elicio's approach is based on a different technology platform.

Stakeholder Impact

• Shareholders may see a positive impact if the clinical trial results are favorable.
• Patients with pancreatic cancer may benefit from a new treatment option.
• Employees of Elicio Therapeutics are working on a potentially impactful therapy.

Next Steps

• The company will conduct an interim analysis of the Phase 2 AMPLIFY-7P study in the first half of 2025.
• The company will continue to work towards bringing the ELI-002 vaccine to cancer patients.
• The company will continue to develop additional off-the-shelf therapeutic cancer vaccines.

Key Dates

Keywords

ELI-002, pancreatic cancer, immunotherapy, KRAS, cancer vaccine, clinical trial, AMPLIFY-7P, disease-free survival, AMP technology, biotechnology